

## REFERENCES

القرآن الكريم: نزل به جبريل الأمين من رب العالمين على سيدنا محمد صلى الله عليه وسلم . سورة الكهف آيه ٦٤ و ٦٥ و ٦٦ و ٦٧ و ٦٨ .

**Abdel Aziz M.T., Ali A.H.M., Saad S.F. and Tadros K. (1981):**  
*Report on fluorimetric method for determination of catecholamines in tissue. J. Egyptian medical Assoc. Accepted for publication 12, 8, 1981.*

**Andermann E. (1980):** *Multifocal inheritance in the epilepsies. Epilepsia (Amsterdam) 1:418-477.*

**Anderson V. E., Hauser W. A., Olofsson E., and Rich S. S. (1990):**  
*Genetic aspects of epilepsies. In: Sillanpaa M., Johannessen S.I., Blennow G., Dam M.(Eds) pediatric epilepsy. Wighston Biomedical publishing, Petersfield, England, P 37-56.*

**Annegers J.F., Grabow J.D. and Groover R.V. (1980):** *Seizures after head trauma. Neurol. 30; 683 - 689 .*

**Anton A.H. and Sayer D.F. (1964):** *The distribution of monoamines in various animals and method for their determination. J. Pharmacol. Exp. Therap. 145, 326-331.*

**Bachmann D.S. (1982):** *Use of valproate in treatment of infantile spasms. Arch. Neurol. 39, 49-52.*

- Baf M.H.M., SubHash M.N.K., Lakshamana K.M. and Rao S.R. (1994):** *Sodium valproate induced alterations in monoamine levels in different regions of the rat brain. Neurochem. 24, 1, 67-72.*
- Barolin G. S. and Pateisky K. (1969):** *Geschwister mit myoklonus-koerperchenkrank-neit. W. Z. Nervenheilk 27, 1-8*
- Barolin G. S. and Karbowski, K. (1973):** *Okzipitale kriser im Grenzland der Epilepsie Z. EEG-EMG. 4, 1-8 .*
- Benna P., Ferrero P., and Bianco C (1984):** *Epidemiological aspects of epilepsy in children. Pan Med. 26,113-118.*
- Berkovic S.F., Baldin P.F., Jones D.B., Smallwood R.A. and Vajda F.J. (1983):** *Hepatotoxicity of sodium valproate. Clin. Exp. Neurol. 19, 192-7.*
- Bernnan T.J., Morris M. and Heywood J.R. (1985):** *GABA agents inhibit central sodium induced vasopressin dependent increases in arterial blood pressure. J. Pharmacol. Exp. Ther. 233, 2, 664-71.*
- Binsard N., Livet M. O. And Saint-Jean M. C. (1985):** *Epileptic syndromes in infancy, childhood and Adolescent. Clin. Neurophysiol. 46, 34 P.*

- Bohan T.P., Millington D.S. and Roe C.R. (1994):** *Valproyl carnitine, a novel metabolite of valproic Acid. Ann. Neurol. 16:39.*
- Boumas B. (1971) :** *Clin. Chem. Acta, 1971.*
- Briere R., Sherwin A. L., Oliver A., Robitille Y., Quesney L. F. And Reader T. A. (1986):** *Alpha-1 adrenoceptors are decreased in human epileptic foci. Anni. Neurol. 19, 26-30.*
- Bromann J. (1988):** *Electrophysiology of GABA<sub>A</sub> and GABA<sub>B</sub> receptor subtypes. Trends in Neurosciences. 11, 112-116.*
- Brooke O.G. (1988):** *Delayed effects of head injuries in children BMJ. 296:984.*
- Browne T. R., Penry J. K (1973):** *Benzodiazepines in The treatment of epilepsy. A review Epilepsia, 14,277.*
- Browne T.R. (1980):** *Valproic Acid. N. Eng. J. Med. 302, 661-666.*
- Bryson S.M. Verma N., Scott R.J.W. and Rubin P.C. (1983):** *Pharmacokinetics of valproic acid in young and elderly subjects. Br. J. Clin. Pharmacol. 16, 105-5.*
- Buckle V. J., Fulida N., Ryder-cook ,A- S (1989):** *chromosomal localization of G A B A receptor subunits genes, relationship to human genetic neuron. Neurol. 3,647-654.*

- Callaghan N., Kenny R.A., O'Neill B., Crowley M. And Goggin T. (1985):** *A prospective study between carbamazepine, phenytoin, and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. J. Neurol. Neurosurg. Psychiatry 48, 639-644.*
- Calloni M.V., Porazzi D. and Rovetta P. (1982):** *further observations on focal onset of eclamptic Electroencephalography Clin. Neurophysiol . 54,1 p.*
- Chadwick D. and Turnbull D. M. (1985):** *The comparative efficacy of antiepileptics drugs for partial and tonic seizures J.Neurosurg., and Psychiat 48, 1063.*
- Chapman A., Keane P.E., Meldrum B. S., Simland J. And Vernieres J.C. (1982):** *Mechanism of anticonvulsant action of valproate. Prog. Neurobiol. 19, 315-359.*
- Chen G., Ensor C. R. And Bohner B. (1954):** *A Facilitation action of response on central nervous system. Soc. Exp. Biol. Med. 86, 507-510.*
- Cohen A.F., Land G.S. and Breimer D.P. (1987):** *Lamotrigine, a new anticonvulsant, pharmacokinetics in normal humans. Clin. Pharmacol. Ther. 42, 535-541 .*

- Cooper A.J. (1986):** *Advances in the assessment of organic causes of impotence Br. J. Hosp. Med. 36, 186-92.*
- Cosden R., Gorden A. H. And Martin A. J. P. (1944):** *Biochem. J. 224-232.*
- Coursin D.B. (1954):** *Convulsive seizures in infants with pyridoxine-deficient diet. JAMA 154, 406.*
- Covanis A, Gupta A. K., Jeavons P. M. (1983):** *Sodium valproate : Monotherapy and Polytherapy Epilepsia 23,693-720.*
- Dale B.M., Purdie G.H. and Rischbith R. H. (1978):** *Fibrinogen depletion with sodium valproate. Lancet I, 316-7.*
- Daniel J.C. (1971):** *Methods in mammalian embryology. The Daniel J.C., John W.S. (eds), San Francisco, Toronto, Singapore P. 531.*
- Dansky L.V., Andermann E., Sherwin A. And Andermann F. (1987):** *Anticonvulsants, folate levels and pregnancy. Ann. Neurol. 21, 176-82.*
- Davidson D. L. W. (1989):** *A comparative multicenter clinical trial of sodium valproate and carbamazepine in adult onset epilepsy. In 4Th international symposium on sodium valproate and epilepsy, Edited by Chadwick D., Royal society of Medicine services Limited, London, New York P.P. 114-121.*

- Dawson A.B. (1926):** *A note on the staining of the skeleton of cleared specimens with alizarin red. Stain Technol., 19, 123-124.*
- Delorenzo R. J. (1986):** *A molecular approach to calcium signal in brain: relationship to synaptic modulation and seizure discharge. Adv. Neurol 44, 435-464.*
- Dent C. E. (1947):** *The amino aciduria in Fanconi syndrome. A study making extensive use of techniques. Biochem. J. 41, 240-53.*
- Doose H., Gerken H., Horstmann T. and Volke E. (1973):** *Genetic Factors in spike-wave absences. Epilepsia (Amsterdam). 14,57-75.*
- Dreifuss F.E. (1987):** *Fatal Liver failure in children on valproate. Lancet 1,47-8.*
- Dreifuss F.E. and Langer D.H. (1987):** *Hepatic considerations in use of antiepileptic drugs. Epilepsia 28, Supp. 2, 523-529.*
- Dreifuss F.E., Santilli N., Langer D.H., Sweeney K.P., Moline K.A. and Menander K.B. (1987):** *Valproic acid and hepatic fatalities. Neurol. 37, 379-85.*
- Eeg-Olofsson O., Safwenberg J., and Wigertz A. (1982):** *HLA and epilepsy. Epilepsia (New York) 23, 27-34.*

**Fahmy E. M., Mansour M. E., Awara W. M., Bahreez A. F., ElGazar A. A., Fathy H. (1994):** *The role of cortical acetylcholine and GABA on the initiation and maintenance of status epilepticus induced experimentally. Benha Med. J., Vol. 11, No. 3, Sept.*

**Federick J. (1973):** *Epilepsy and pregnancy. Br. Med. J. 2, 442-8.*

**Feeney D. M. And Walker A. E. (1979):** *The prediction of post-traumatic epilepsy. Arch Neurol. 36, 8-12.*

**Feldman R.S. and Quenzer (1984):** *Fundamentals of neuropsychopharmacology "Sunauer Associates Inc. Sunderland Massachuesetts. P. 32-105.*

**Fisher R.A., (1958):** *Statistical methods for research workers 14th Edition. Oliver and Bayal, Edinburgh London P. 15--67 .*

**Forsgren L. (1990):** *Prospect incidence study, and clinical characterization of seizures in newly referred adults. Epilepsia 31,292-301.*

**Forster F.M. (1945):** *Arch. Neurol. Psychiat. 54, 391.*

**Frii M. L. (1984):** *Antiepileptic drugs and teratogenesis. Acta Neurol. scand 94,39-43.*

- Gale K. (1989):** *GABA in epilepsy. Epilepsia 30 (supp 3) 51-511.*
- Goldstein D., Nadi N. S., and Stull R. (1988):** *Levels of catechols in normal and epileptic regions of human brain. J. Neurochem. 50, 225-229.*
- Harchovy R. A., Frost J.D, Kellaway P., and Zion T. E.(1979):** *A controlled study of Prednisone Therapy in infantile Spasms. Epilepsia 20,403.*
- Harding G. F. A., Herrick C. E, and Jearons P. M.(1978):** *A controlled Study of The effect of Sodium valproate on Photosensitive epilepsy and its Prognosis. Epilepsia 19,555.*
- Harranz J. L., Arteaga R., and Armijo J. A (1982):** *side effects of -sodium valproate in monotherapy controlled by plasma levels Epilepsia ,23,203-14.*
- Hauser W. A., Annegers J. F., and Kurland L. T. (1984):** *The incidence of epilepsy in Rochester, Minnesota 1935-79. Epilepsia 25,666.*
- Heller A.L., Ben-Hur T., and Reches A. (1994):** *Valproate encephalopathy and hypocarnitinaemia in diabetic patients. J. Neurol 241, 567-569 .*



- Henriksen O. And Johannessen S.I. (1980):** *Clinical observation of sodium valproate in children: An evaluation of therapeutic serum levels In: Antiepileptic therapy : Advances in drugs monitoring Johannessen S.I., Morselli P.L., Pippenger C.E., Richens A., Schmidt D., meinardi H. Eds., New York: Raven Press, 253-61.*
- Henry J. (1964):** *Clin. Chem., Harper & Row publishers, New York, 1964, p 181.*
- Hiramatsu M., Fujimoto N. And Mori A. (1982):** *Catecholamine level in cerebrospinal fluid of epileptics. Neurochem. Res. 7, 157-171.*
- Hjelm M., Oberholzer V., Seakins J., Thomas S. And Kay T. D. S. (1986):** *Valproate induced inhibition of urea synthesis and hyperamonia in healthy subjects. Lancet, II, 859.*
- Holmes L.B., Horvery E.A., Brown K.S. Hayes A.M. and Khoshbin S. (1994):** *Anticonvulsant Teratogenicity . Life Science 19, 1200.*
- Hosking G.C. (1989):** *A comparative multicentre clinical trial of soduim valproate and carbamazepine in newly diagnosed epilepsy. In 4th international symposium on soduim valproate and epilepsy, Edited by Chadwick D., 1989, published by Royal Society of Medicine Services limited. PP. 71-80.*
- Invitti C., Danfsi L., Dubini A. and Cavagnini F. (1988):** *Neuroendocrine effects of chronic administration of sodium valproate in epileptic patients. Acta Endocrinol. 118, 381-8.*

- Johannessen S.I. (1977):** *Preliminary observations on valproic acid kinetics in patients with epilepsy. Arzneimittelforschung 27, 1083-1085.*
- Johnson R. T. (1982):** *Viral infections of the nervous system. Johnson RT (Ed.) New York, Raven Press.*
- Juul- Jensen P., and Foldspang A. (1983):** *Nature history of epileptic Seizures. Epilepsia 24,297-312.*
- Kaneko S., Otani K., Fukushima Y., Ogawa Y., Nomura Y. Ono T., Nakane Y., Teranishi T. And Goto M. (1988):** *Teratogenicity of antiepileptic drugs: Analysis of possible risk factors. Epilepsia 29, (4): 459-467.*
- Kaufman. D., McGinnis J. F., and Krieger N. R (1989):** *Brain glutamate decarboxylase clon in Lambda- gt 11 fusion produces GABA. Science 237, 1138-1140.*
- Keane P.E., Simiand J., Mendes E., Santucci V. And Morre M. (1983):** *The effects of analogues of valproic acid on seizures induced by pentylenetetrazole and GABA content in brain of mice. Neuropharmacol. 22, 875-879.*
- Kenpe E., mack G., Schleef C. And Mandel P. (1982):** *Effect of valproic acid on brain serotonin metabolism in rats. Pharmac. Biochem. Beh. 17, 49-52.*

**Kind P.R.N. and King E.G. (1954):** *J. Clinical. Path.* 7, 322.

**King D. W., Dyken P. R., Spinks I. L., and Murvinj A. J. (1985):**  
*Infantile spasms, Ictal phenomena. Pediatric Neurol.* 1, 213-218.

**Koch S., Hartmann A., Jäger-Roman E., Rating D. And Helge H. (1982):** *Major mal formations in children of epileptic parents. Science* 185, 573-82.

**Koe B. K. And Weissman A. (1966):** *Achlorophenylalnine: A specific depletor of brain serotonin. J. Pharmacol. Exp. Therap.* 154. 499-516.

**Kukino K. And Deguchi T. (1977):** *Effects of sodium propyl acetate on gamma-aminobutyric acid and biogenic amines in rat brain. Chem. Pharm. Bull.* 25, 2257-2262.

**Laidlaw J., Richens A. and Chadwick D. (1993):** *General principles in the drug treatment of epilepsy. In A Textbook of Epilepsy, Eds: laidway J., Richens A. And Chadwick D. 5 th ed., Churchill Livingstone. Eden Burgh London Madrid Melbourne New York and Tokyo. Ch. 15 P.P. 495-559.*

**Lee T. K. Y., Nakasu D., and Jefree M. A (1989):** *Indolent, a cause & epilepsy. Arch. of disease & child.* 64,1666-71.

- Lennox, W. G. and Lennox M. A (1960):** *Epilepsy and related disorders. Epilepsia 15, 23.*
- Lesser R. P., Lueders H., Dinner D. S. And Morris H. H. (1985):** *Epileptic seizures due to thrombotic and embolic Cerebrovascular disease in older patients. Epilepsia 26, 622-630.*
- Levy R.H., Lai A.A. (1982):** *Valproate: absorption, distribution and excretion In Antiepileptic drugs: (Woodbury D.M., Penry J.K., Ppenger C.E., Eds).. New York Raven Press, 555-65.*
- Lewis J.R. (1978):** *Valproic Acid: A new anticonvulsant agent. JAMA 240, 2190-2.*
- Lin- Fu J.S.(1982):** *the evolution of childhood lead poisoning. In lead absorption in children eds J.J. Chisolm, and D.M.O Hara Baltimore P.P 1-10.*
- Loke J., Merrill J.P., and Tyler H.R (1961):** *Neurologic complications of acute uremia. Arch Int. Med. 108,519-530*
- Lothman E.W. (1993):** *Epilepsy: Impaired synaptic inhibition and/or Enhanced synaptic inhibition. Epilepsia 34, Suppl (6), 2.*
- Louw D., Sutherland G. R., Blavin G. B., and Girvin J. (1989):** *A study of monoamine metabolism in human epilepsy. Cand. J. Neurol. Sci. 16, 394-379.*

- Lovell R. A. And Elliot K. A. C. (1963):** *Br. Med. Bull.* 29, 2.
- Löscher W., Frey H.H., Reiche R. And Schultz D. (1983):** *High anticonvulsant potency of GABA mimetic drugs in Gerbils with Genetically determined Epilepsy. J. Pharmacol. Exp. Ther.* 226, 3, 839-844.
- Löscher W. And Nau H. (1983):** *Distribution of valproic acid and its metabolites in various brain areas of dogs and rats, after acute and prolonged treatment. J. Pharmacol. Exp. Ther.* 226, 845-854.
- Löscher W. (1985):** *Valproic acid. In Antiepileptic drugs (Frey H.H. and Janz D. eds) Handbook of experimental pharmacology vol. 74, springer-verlag, Berlin, P.P. 507-537.*
- Löscher W., Honack D., Taylor C.P. (1991):** *Gabapentin increase GABA turnover in several regions of rat brain. Brain Res.* 341, 473-478.
- Maccario M. (1968):** *Neurological dysfunction associated with non ketotic hyperglycemia. Arch. Neurol.* 19, 525-534.
- Macdonald R.L. (1988):** *Anticonvulsant drug actions on neurons in cell culture. J. Neural. Transm.* 72, 173-183.

- Macdonald R.L. and Bergey G.K. (1979):** *Valproic acid augments GABA mediated postsynaptic inhibition in cultured mammalian neurons. Brain Res. 170, 558-62.*
- Magnert E.W., Marczynski T.J. and Browing R.A. (1975):** *Advances In Neurology, Ed. Magnert E.W., Raven press New York, Vol. 13 P.P. 49-147.*
- Marciani M. G., Anderrrman F. G. (1985):** *Patient of seizure activation after withdrawal of antiepileptic medication. Neurol. 35,1537-1543.*
- Mattson R. and Cramer J.A. (1985):** *Epilepsy, sex hormones and antiepileptic drugs. Epilepsia 26, (Suppl 1), 240-51.*
- Mattson R. H., Cramer J. A., Collins J. A, (1985):** *Comparison of carbamazepine, phenobarital, phenytoin and primidone in partial and secondary generalized tonic clonic seizures. New Eng. J. of Med. 313,145.*
- Mattson R.H., Cramer J.A., and Collins J.F. (1992):** *A comparison of valproate with carbormazepine for the treatment of complex partial seizures and secondary generalized tonic-clonic seizures in adults. New Engl. M.J. 327; 765-771.*
- McGeer P. L and McGeer E. G. (1989):** *Aminoacid transmitters. in Basic Neurochemistry Ed. by siegel G, Agraoff B. and ALbers R. W. Raven press New York P. P. 311- 360.*

- McKusick V. A. (1989):** *Mendelian inheritance in man. 7th ed.*  
*Baltimore: John Hopkins University Press.*
- McMillan V. (1979):** *The effect of anticonvulsant valproic acid on cerebral indol amine metabolism* *Physiol. Pharmacol.*, 57, 843-847.
- McNamara J. O., Bonhaus D. W., Crain R. L., Gellman G. L. And Shin C. (1985):** *The kindling model of epilepsy.* *Rev. Clin. Neurobiol.* 1,341-393.
- Meldrum B. S. (1984):** *Aminoacid transmitters and new approaches to anticonvulsant drug action.* *Epilepsia* 25 (suppl2) S140- S149.
- Meldrum B. S. (1986):** *Cell damage in epilepsy and the role of calcium in cytotoxicity.* *Adv. Neurol.* 44, 849-855.
- Merritt H.H (1942):** *Sodium biphenyl hydantoinate in the treatment of convulsive disorders.* *J.AMA.* 111, 1068.
- Meyer, F. B. (1989):** *Calcium, neuronal hyperexcitability and ischemic injury.* *Brain Res. Rev.* 14, 227-243.
- Miller F.R. (1937):** *J. Physiol.*, 91, 212.
- Mohr E., and Corcoran M. E. (1981):** *Depletion of noradrenaline and amygdaloid Kindling.* *Exp. Neurol* 72, 507-511.

- Monnet P, David M, Philippe N., Deehavanne M., Floret D., Renaud H, Trezeciak M. C., Brazier J. L., Bourdillon D. (1979):** *Alterations de L'hémostase Lors des Traitements au dipropylacetate de sodwm. Pediatric 34,603-20.*
- Mori A., Hitomatsu M., Namba S., Nish Imoto A., Ohmoto J., Mayonagi Y., and Sakura T. (1987):** *Decreased dopamine levels in the epileptic focus. Res. Commun. Chem. Path. Pharmacol. 56, 157-164.*
- Moroni T., Tanganella S., Antonelli T., Caria V., Bianchi N. And Beani A. (1982):** *Modulation of cortical acetylcholine and GABA release in freely moving guinea pigs, effects of clonidine and other adrenergic drugs. J. Pharmacol. Exp. Ther. 227, 435-440.*
- Morselli M.G., Lioyed K.G., Löscher W., Meldrum B.S. and Reynolds E.H. (1981):** *Neurotransmitters, seizures and epilepsy. Reynolds E.H. (editor) Raven press, new York.*
- Nau H., Zlerer R., Spleimann H., Neubert D. And Gansau C.H. (1981):** *A new model of embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant rate administration in the mouse using human therapeutic dose and metabolic concentrations. Life Seine 29, 2803-14.*
- Ndegwa D., Rust J., Golombok S. And Fenwick P. (1986):** *Sexual problems in epileptic woman. Ann. Med.-Physiol, 112, 657-96.*



- Neal J. M. (1987):** *Anticonvulsants., In medical pharmacology at a Glance, Editors, Neal J.M., first edition, Blackwell scientific publications U.S.A., pp. 52-53 .*
- Niedermeyer E. (1991):** *The Epilepsies, diagnosis and management, Niedermeyer E. (Editor), Urban, Shwarzenberg., Bultimore, Munich Ch. 4, P.P. 51-80.*
- Nitsche V. And Mascher H. (1982):** *The pharmacokinetics of valproic acid after oral and parenteral administration in healthy volunteers. Epilepsia 23, 153-62.*
- Noebels J. L., and Sidman R. L. (1979):** *Inherited epilepsy: spike wave and focal motor seizures in the mutant mouse tottering. Science 204, 1334-1336.*
- Nutt D.J., Cowen P.J. and Green A.R. (1981):** *Studies of post-ictal rise in seizure threshold. Eur. J. Pharmacol. 71, 287-290.*
- Olsen R.W (1982):** *Drug interaction at G A B A receptor- ionophore complex AM. Rev. Pharmacol Toxicol. 22,245-277.*
- Pertin J. B., and Delorenzo. R. J. (1990):** *Calcium and epilepsy In Recent Advances in Epilepsy, Editors, Redley T. A., and Meldrum B. S. 5 th Edition, Churchill Livingstone, Edinburgh, London PP 32.*

- Perucca E., Gatti G., Frigo G.M. and Cerma A. (1978):**  
*Pharmacokinetics of valproic acid after oral and intravenous administration. Br. J. Clin. Pharmacol. 5, 313-18.*
- Pinsord N., Livet M.O., and Saint Jean m. (1985):** *A case of cerebral lipidosis with an atypical presentation. Electroencephalogr. Clin. Neurophysiol. 46; 38 P.*
- Plomin R., Defries J. c., Mcclean G. E. (1990):** *Behavioral genetics GAMA 13, 21-35.*
- Pollack M. A, Zion T. E, and Kellaway P. (1979):** *long term Prognosis of Patients with infantile Spasms Following A C T H Therapy Epilepsia 20,225.*
- Pope A., Morris A.A., Jasper M.H., Elliott K.A.C. and Penfield A. (1947):** *Res. Publ. Ass. Nerv. Ment. Dis., 26, 218. Quoted from Thompson R.H.S. and Cumings J.N., Chap. 13, Diseases of the nervous system, Page 453 in Thompson R.H.S., and Wooton T.D.P., Biochemical disorders in human diseases. Academic press New York (1970).*
- Poulton J. (1989):** *Epilepsy Genes. In, 4Th international symposium on sodium valproate and Epilepsy, Ed, Chadwicck D., Royal society of medicine services, London, pp 262-269.*

- Ramsay R.E. (1984):** *Controlled and comparative trials with valproate. Epilepsia 25 (Supp. 1), 540-543.*
- Rangel- Guerra R.A., Gareia- Hernandez P.A, Mortinez H.R., and Villareal J.Z.(1989):** *Epilepsy and thyrotoxicosis. Epilepsia (New York) 30,733.*
- Rapin I., Goldfischer S., Katzman R., Engel. J. And O'Brian J. S. (1975):** *The cherry-red spot myoclonus syndrome. Ann. Neurol. 3, 234-242.*
- Raworth R. E., Birchall G. (1978):** *sodium valproate and platelet count. Lancet, :670-1.*
- Reinmann W., Zumstein A., and Starke K. (1984):** *GABA can inhibit or facilitate dopamine release in C.N.S. J. Neurochemistry 39, 691-700 .*
- Reitman S. And Frankel S. (1957):** *Amer. J. Clin. Path. 28:56.*
- Rettie A.E., Rettenmeier A.V., Howald W.N. and Baillie T.A. (1987):** *Cytochrome P. 450-Catalysed formation of VPA, atoxic metabolite of valproic Acid. Science 235, 890-3.*
- Reynolds E. H. and shoruon S. D. (1992):** *Monotherapy or polytherapy for epilepsy. Epilepsia 22,1-10.*

**Reynolds E.M. (1978):** *Drug Treatment of epilepsy. Lancet, ii, 721.*

**Roberts E., and Frankle S. (1950):** *J. Of Am. Physiology 55-63 .*

**Roberts E. And Guibaud P. (1982):** *Maternal valproic acid and neural tube defects. Lancet 1, 272-5.*

**Saunders M. And Rawson M. (1970):** *Sexuality in male epileptics J. Neurol. Sc. 10, 577-83.*

**Schmidt D. (1982):** *Adverse effects of antiepileptic drugs Schmidt D (ed). New York Raven Press, 240.*

**Scott D., and Cabral R. (1975):** *Development and prevention of seizures after neurosurgical procedures including ruptured cerebral aneurysms. In proceeding of the American Epilepsy Society New York, Dec. 3. 1975.*

**Scott D.A., Gholson C.F., Netchvolodoff C.V., Gonzalez E. And Bacom B.R. (1991):** *Incidental Microvascular steatosis due to valproic acid. Am. J. Gastroent., 86, 4, 500-2.*

**Sherwin A. L., and Van Gelder N. M. (1986):** *Aminoacids and catecholamine markers of metabolic abnormalities in the human focal epilepsy. Adv. Neurol. 44, 1011-1032.*

**Shome B. And Parlow A.F. (1977):** *J. Clin. Endocrinal Metab. 45, 1112-1115.*

- Shorvon S.D., and Roynolds E.M., (1982):** *Early prognosis of epilepsy. Br. Med. J. 285, 1699-1701.*
- Shorvon S.D. (1990):** *Epidemiology, classification, natural history and genetics of epilepsy. Lancet 336, 8714, 3-7.*
- Shucard D. W., Spector S. L., Euwer R. L., Cummines K. R., Shucard J. L. And Friedman A. (1985):** *C.N.S effects of anti-asthma medication- on EEG study . Ann. Allergy 54, 177-184.*
- Simon R.P., Aminoff M.J. and Benowitz N.L. (1984):** *Change in plasma catecholamines after tonic clonic seizures. Neurol. 34, 255-257.*
- Simpson L.L. (1976):** *Amphetamine and related stimulants. In drug treatment of mental disorders, Chapter II, Edited by Simpson L.L., Raven press, New York P.P. 15.*
- Sommer B., Kelnanen K., Verdoorn T. (1990):** *A cell-specific functional switch in glutamate-operated channels of C. N. S. Science 249, 1580-1585.*
- Sussman N.M. and McLain L.W. (1979):** *A direct hepatotoxic effect of valproic acid. JAMA 242, 1173-4.*
- Taylor D. (1969):** *Sexual behavior and temporal lobe epilepsy. Arch Neurol. 21, 510-6.*

- Teramo K., and Hiilesmaa V. K. (1982):** *Pregnancy and fatal complications in epileptic pregnancies. In Janz D., Dam M. Richens A, Bossi L. , Helg H. and Schmidt D. Epilepsy , pregnancy and The child. New York- Raven press. 53-59.*
- Thompson P.J. and Trimble M.R. (1981):** *Sodium valproate and cognitive functioning in normal volunteers. Br. J. Clin. Pharmacol. 12, 818-24.*
- Tower D.B. and McEachern D. (1949):** *Cand. J. Res. 27, Sect E, 120.*
- Tower D.B. and Elliott, K.A.C. (1952):** *J. Appl. Physiol. 4, 669.*
- Tower D.B. (1956):** *Neurochemical aspects of pyridoxine metabolism and function. Am. J. Clin. Nutr. 4,329.*
- Tower D.B. (1986):** *Neurochemistry of epilepsy. World Neurol. 3, 185-194.*
- Tsuji J., Balagat K. And Sadone L. (1963):** *JAMA 183, 659-661.*
- Van den Berg B. J., and Yerushalamy J. (1969):** *Studies on convulsive disorders in young children. Ped. Research 3,298-304.*
- Vane Sweden B., and Dumon- Radermecker M. (1982):** *The E E G in chronic psychotropic drug intoxication. Clin. Electroencephalog. 13,206-215 .*

- Victor M., and Brausch J.(1967):** *the role of abstinence in the genesis of alcoholic epilepsy* *Epilepsia (Amsterdam)* 22,623-629 .
- Wada J. A., Balzamo E., Meldrum B. S. And Naquet R. (1972):** *Behavioral and electrographic effects of L-5-hydroxytryptophan and D, L-parachloro-phenylalanine on epileptic.* *Clin. Neurophysiol.* 33, 520-526.
- Walker A. E. (1962):** *Post-traumatic epilepsy . world Neurol.* 3, 185-194.
- Walton J. S. (1953):** *The electroencephalographic sequelae of spontaneous subarachnoid hemorrhage.* *Electroencephalogr. Clin. Neurophysiol* 5, 41.
- Walton J. S. (1985):** *Paroxysmal and convulsive disorders. In Brains diseases of the nervous system, Editor, Walton J.S., 9th edition English Language Book Society / oxford University press Ch. 22, PP 609-635.*
- Weissbach H. (1965):** *Determination of serotonin by spictrofluorophotometric methods. In Medical Research Chicago, Year Book Publisher Inc. Volume 9, P. 178.*
- Wells P.G., Zubovits J.T., Wong S.T., Nolinari L.M. and Ali S. (1989):** *Modulation of phenytoin Teratogenicity and embryonic covalent binding by acetylsalicylic acid, caffeic acid, and  $\alpha$*

*Phenyl-N-t-butylintrone implications for bioactivation by prostaglandin synthetase. J. Toxicol Pharnacol 97, 192-202.*

**Wilson J.G. (1972):** *Embryological consideration in teratology in: Principles and Techniques (Wilson J. G. And Warkany J. Eds). University of Chicago Press, Chicago and London P.P. 251-272.*

**Yerby M. S. (1992):** *Risks of pregnancy in woman with epilepsy. Epilepsia 33, (1), 523-527.*

**Zwang H. J. And Cohn D. (1981):** *Eletroencephalographic changes in acute water intoxication. Clin. Electroencephalography. 12, 35-40.*